BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. BioNTech SE is among the best biotech stocks

TheFly reported on April 10 that Morgan Stanley slightly increased its price target on BNTX from $125 to $126 while maintaining an Overweight rating. The adjustment was part of broader updates across its biopharma coverage, incorporating recent industry data trends from IQVIA and incorporating intra-quarter performance indicators ahead of first-quarter earnings across the sector.

Moreover, on April 12, BioNTech SE (NASDAQ:BNTX) and its partner DualityBio reported positive findings from a Phase 2 cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303), an antibody-drug conjugate targeting HER2-expressing advanced endometrial cancer. The study included patients whose disease had progressed after prior chemotherapy, with or without checkpoint inhibitor therapy, as part of a broader early- and mid-stage clinical program across multiple solid tumors.

BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models

A scientist in a lab conducting research on cell-based therapeutics and biotechnology.

Results showed meaningful anti-tumor activity, with confirmed responses observed across different levels of HER2 expression and consistent outcomes regardless of prior immunotherapy exposure. The treatment demonstrated a manageable safety profile. In a key efficacy measure, the cohort met its primary endpoint, showing a confirmed objective response rate of 49.3% in previously checkpoint-treated patients and 47.9% overall, along with a median progression-free survival of 8.1 months. The data were scheduled for presentation at a major oncology meeting.

BioNTech SE (NASDAQ:BNTX) is an AI-driven biotechnology company focused on next-generation immunotherapies, including mRNA, antibody-drug conjugates, and cell therapies for cancer and infectious diseases. It integrates advanced AI and supercomputing across drug discovery, clinical development, and manufacturing to accelerate innovation.

While we acknowledge the risk and potential of BNTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BNTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Most Undervalued Healthcare Stocks to Buy Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.